Key Highlights

  • RXRX closed at $3.47 on Friday, down 16.71%, among the session's biggest percentage losers.
  • The AI drug-discovery company was hit by both the AI selloff and biotech weakness.
  • The PHLX Semiconductor Index fell about 3.83% as chip stocks declined an eighth straight session.
  • The 10-year Treasury yield near 5.10% pressured long-duration, pre-profit names.

Recursion Pharmaceuticals (NASDAQ:RXRX) shares closed Friday, October 16, 2026, at $3.47, down 16.71% on the day, a decline that placed the AI-driven drug-discovery company among the session’s biggest percentage losers. The move sat at the intersection of two of the day’s most powerful forces: a renewed selloff in AI-linked equities and a broad risk-off retreat in biotech, both intensified by higher Treasury yields. That combination, rather than any single company announcement, is what best explains the drop.

Two Themes, One Day

Friday was defined by weakness in AI, semiconductor and “neocloud” data-center names, which dragged the technology-heavy indexes lower. The Nasdaq Composite fell about 573 points, or 2.14%, snapping a four-week winning streak and ending the week down roughly 4.5%. The S&P 500 lost 1.09% to 7,659.44 and shed about 2% on the week, while the Dow Jones Industrial Average held up better, down just 0.34% to 52,002.41. The PHLX Semiconductor Index dropped about 3.83% as chip stocks fell for an eighth straight session, and the selloff extended across the AI ecosystem, hitting both the hardware supply chain and the companies whose investment thesis rests on applying artificial intelligence at scale.

Recursion occupies an unusual position that left it exposed to pressure from both directions. As a company using AI and machine learning to accelerate drug discovery, it is sensitive to sentiment around artificial intelligence, which turned sharply negative on Friday. At the same time, it is a clinical-stage biotech, and biotech was among the groups hit hardest by the day’s macro backdrop.

Hotter-than-expected CPI and PPI readings kept the Federal Reserve’s path uncertain, and the 10-year Treasury yield sat near 5.10%, up about two basis points on the day. Higher long-term yields weigh heavily on companies whose expected profits lie far in the future, because those distant cash flows are discounted more steeply. For a long-duration, pre-profit name that is simultaneously an AI story and a biotech story, a session that punished both themes was especially unforgiving.

A Low Price Magnifies the Move

The low share price added to the magnitude of the move. A stock trading near three and a half dollars tends to post larger percentage swings than higher-priced shares, so a bout of sector-driven selling can produce a double-digit decline without requiring any company-specific trigger. That is consistent with what happened on Friday: the available information points to no confirmed earnings release, trial readout, regulatory decision, partnership, financing or analyst action tied to Recursion for the October 16 session.

Recursion was also absent from the day’s areas of strength. Leadership came from energy, as WTI crude rose about 3.4% to roughly $101 a barrel on reported tensions near the Strait of Hormuz, lifting oil producers and oilfield services, and from defense and aerospace names that gained on the same Middle East tensions. Consumer staples attracted defensive flows across the week, and gold firmed modestly. None of those rotations benefited an AI-focused biotech, which instead fell with the two cohorts the market was most eager to shed.

When AI and Biotech Fall Together

Recursion’s decline reflected the simultaneous selloff in AI-linked names and the risk-off pressure on biotech, compounded by higher yields and the volatility of a low-priced stock. It was not, on the confirmed information, a reaction to any specific company news.